Background: Proper breakdown of starch by hydrolytic enzymes to give glucose has profound implications for avoiding Type 2 diabetes and obesity. Results: Starch digestion by the different human enzymes is controlled using a panel of compounds. Conclusion: Inhibitors can be used to switch off selectively the different enzyme activities. Significance: More refined control of starch hydrolysis with the aim of slow glucose delivery is possible.
Starch is the major carbohydrate storage compound from plant seeds and tubers that is used by animals, including humans, as a major source of dietary energy in the form of glucose. Starch can supply as much as 70-80% of the calories in the human diet (1) . Several enzymes are involved in the process of starch hydrolysis to glucose in the gastrointestinal (GI) tract. First, the salivary and pancreatic α-amylases hydrolyze starch molecules to linear maltooligosaccharides (LM, consisting mainly of maltose and maltotriose), and α-1,6 branched oligosaccharides (α-limit dextrins, αLDx, which cannot be further hydrolyzed by the α-amylases. In waxy starches with no amylose, the amount of linear maltooligosaccharides is approximately three times higher than the branched maltooligosaccharides in the α-amylolyzed products (2) . Glucose is not a major product of the α-amylase reaction and thus the mixture of linear maltooligosaccharides and branched α-limit dextrins (LM-αLDx) must be further hydrolyzed to glucose by the combined exo-hydrolytic actions of maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) enzyme complexes in the small intestine (3, 4) . Each intestinal α-glucosidase complex consists of two family GH31 catalytic modules, the N-terminal subunits (ntMGAM and ntSI) and C-terminal subunits (ctMGAM and ctSI) (5, 6) . Both MGAM and SI N-terminals are connected to the brushborder epithelial cells via O-glycosylated stalk domains (7) . All four α-glucosidases have, to varying extent, the ability to hydrolyze α-1,4 linkages which comprise the linear chains of starch with exo-hydrolytic activity to release glucose, ctMGAM has the highest hydrolytic activity on α-1,4 linkages among the four mucosal α-glucosidases, especially on longer maltooligosaccharides. In addition, ntSI has debranching activity on α-1,6 linked structures, acting from the non-reducing end to release glucose, while ctSI is involved in sucrose digestion (8) . The individual physiological contributions of the four subunits, and the extent to which they act in cooperation under different physical or dietary conditions, are unknown.
Inhibition of pancreatic α-amylase and/or intestinal α-glucosidase activity is currently applied to the treatment of Type 2 diabetics (noninsulin-dependent) to adjust glucose levels in the blood stream (9, 10) . As MGAM and SI are involved in producing glucose from LM-αLDx, regulation of individual mucosal α-glucosidase activities is considered to be one of the effective approaches for regulating blood glucose levels (11, 12) . Recent studies by our consortium showed that different mucosal α-glucosidases can be inhibited differently by the same inhibitor, e.g. acarbose (1), ( Figure 1A ) (13) leading to the hypothesis that one might regulate individual α-glucosidase activities with certain inhibitors by partially or wholly inhibiting either one, two or three of the four α-glucosidase activities while leaving the remaining one or more subunits active, a concept we advanced as "toggling" (14, 15) . That is, through the judicious action of selective inhibitors, a fast digesting subunit or subunits can be inhibited to place the onus of digestion on slower digesting subunits. It follows that the rate of starch digestion and glucose release to the body could be controlled.
Recently, a relatively new class of sulfonium-ion glucosidase inhibitors, including salacinol (2) (16), ponkoranol (3) (17), kotalanol (4) (18), de-O-sulfonated kotalanol (5) (18b,19), de-O-sulfonated salacinol (6) (20), and de-Osulfonated ponkoranol (7) (21a,b) ( Figure 1A ) have been isolated from the roots and stems of the Salacia species, a plant widespread in Sri Lanka and Southern India used in traditional Ayurvedic treatment of Type 2 diabetes (22).
The compounds were shown to be inhibitors of intestinal α-glucosidase enzymes that attenuate the undesirable spike in blood glucose levels that is experienced by diabetics after consuming a meal rich in carbohydrates. Previously, the compounds have been shown to be stronger inhibitors of ntMGAM, with K i values in the low micromolar range (i.e., 0.03-0.19 µM) compared to acarbose (1) (K i = 62±13 µM) (23) (24) (25) (26) (27) (28) . In addition, the de-O-sulfonated compounds (6) (7) (8) were either equivalent or better inhibitors than the parent sulfonated compounds (2-5) (14, 29) . We have also synthesized the C-3′-β-Omaltose-extended de-O-sulfonated ponkoranol analogue 10 and C-5′-β-O-maltose-extended-de-Osulfonated ponkoranol 11 ( Figure 1B) (15) . The effectiveness of these compounds and acarbose (1) on inhibition of recombinant mammalian MGAM (ntMGAM, ctMGAM) and SI (ntSI, ctSI), using maltose as a substrate, have shown some striking selectivities (15) .
In the small intestine, SI and MGAM are exposed to LM-αLDx, rather than maltose, as substrates. Therefore, an objective of the current work was to explore the role of different inhibitors on MGAM and SI enzyme activities against LMαLDx structures. Furthermore, our interest was to elucidate whether specific inhibitors could affect glucogenesis by selective inhibition of the different enzymes, having shown this property with maltose as a substrate (14, 15) , and to investigate how slow starch digestion, or slow glucose delivery to the body, might be achieved using this concept. We have chosen as representative inhibitors acarbose (1), de-Osulfonated kotalanol (6), C-3′-β-maltose-extended de-O-sulfonated ponkoranol analogue 10, and C-5′-β-maltose extended-de-O-sulfonated ponkoranol 11, and report here their inhibitory effects on recombinant human MGAM and SI using a mixture of the α-amylase degradation products, linear maltooligosaccharides and α-limit dextrins (LM-αLDx) as a substrate.
Methods and materials Materials
Waxy corn starch (WCS), genetically depleted of amylose, (Tate and Lyle, Inc., Decatur, IL, USA) was used as the substrate for producing LM-αLDx. Acarbose was purchased from SigmaAldrich Co. (St. Louis, MO, USA) and other inhibitors (6, 10, and 11) were synthesized as described previously (15,18b) . Human pancreatic α-amylase was purchased from Meridian Life Science, Inc. (Saco, Maine, USA). The glucose assay kit was purchased from Megazyme (Wicklow, Ireland). All chemicals used in this study were of analytical grade.
Methods

Enzyme preparation
Methods for cloning, expression, and purification of human ntMGAM (7) , and ntSI (30) from Drosophila S2 cells as well as mouse ctMGAM, and ctSI were previously reported (14) .
Determination of protein concentration
The protein concentration in the enzyme solution was determined using the Protein Assay Kit (Bio-Rad, CA, USA) according to the Bradford method (31) . Enzyme solution (20 µL) was mixed with 1.0 mL of diluted dye reagent and incubated at room temperature for at least 5 min, and then enzyme activity was measured by absorbance change at 595 nm using a DU 530 Life Science UV/Vis spectrophotometer (Beckman Instruments. Inc., CA, USA)
Production of the mixture of linear and branched maltooligosaccharides (LM-αLDx)
WCS was mixed in 10 mM phosphate buffer (pH 6.9, 10 mg/mL, w/v) and reacted with human pancreatic α-amylase (0.24 U, one unit activity was defined as the amount of enzyme that produces 1 µM of 2-chloro-4-nitrophenyl-α-Dmaltotrioside per min at 37°C) at 37°C for 24 h to produce a LM-αLDx mixture. α-Amylase was inactivated by boiling and the α-amylolysis product was utilized as a substrate for inhibition testing with mucosal recombinant MGAM and SI subunits.
Structural analysis of LM-αLDx by HPAEC
The size distribution of the LM-αLDx from WCS was characterized by high performance anion-exchange chromatography (HPAEC) fitted with an electrochemical detector (ED 40, Dionex, Sunnyvale, CA, USA). Filtered (by 0.22 µm syringe filter) α-amylase-treated WCS sample (25 µL) was injected onto a CarboPac PA-1 pellicular anion-exchange column (Dionex, CA, USA), previously equilibrated in 150 mM NaOH at a flow rate of 1 mL/min. Separation of the LMαLDx structures was achieved using linear gradient mode with 600 mM sodium acetate (in 150 mM NaOH).
Effect of different inhibitors on individual mucosal α-glucosidases
Recombinant α-glucosidases were preincubated with different concentrations of inhibitors (range from 0.5 × 10 -3 to 500 nM) for 30 min before reacting with substrates. A fixed protein amount of each α-glucosidase (30 µg/mL) was incubated with substrate (LM-αLDx or maltose) in 10 mM PBS (pH 6.9, 1 mg/mL, w/v) at 37°C for 1 h. The amount of released glucose from substrate was analyzed by the glucose oxidase/peroxidase (GOPOD) method (32) . Samples without inhibitors (designated as "blank") were assumed to be 100% hydrolyzed.
IC 50 calculation
IC 50 values were calculated using a quadratic polynomial equation with inhibitor concentrations against 50% of released glucose compared to a control sample without inhibitors (33) . IC 50 values were determined based on the same protein amount of recombinant C-and Nterminal MGAM and SI subunits. All analyses were performed in duplicate.
Results and discussion Specific activity of the purified recombinant mucosal α-glucosidases
Purified recombinant C-and N-terminal α-glucosidase solutions were applied to assay enzyme activity. Table 1 shows specific activities (U/mg) of the individual mucosal α-glucosidases (based on glucose release) on maltose and LMαLDx hydrolysis. One unit (U) of enzyme activity was defined as 1 µM of glucose released from maltose or LM-αLDx (1%, w/v) in 1 min (µM/min). ctMGAM had approximately 1.8 -3.8 and 2 -3.6 times higher hydrolysis activity with maltose and LM-αLDx, respectively, as compared to the other α-glucosidases (based on protein amounts). ntSI had the lowest specific activity for both maltose and LM-αLDx hydrolysis amongst the four mucosal α-glucosidases. Previous enzyme kinetic research using maltose as a substrate showed that ctMGAM had the lowest K m value (1.9 mM) (14) and ntSI had the highest K m value (7.1 mM) (30) amongst the four α-glucosidases.
Structural analysis of α-amylase-treated waxy corn starch (WCS)
A mixture of linear maltooligosaccharides and α-limit dextrins, produced from α-amylase reaction on WCS and intended to simulate actual starch digestion products that are generated in the small intestinal lumen, was utilized as the substrate for analyzing the inhibitory effects of mucosal α-glucosidases. Structural analysis of post-amylase small maltooligosaccharides obtained from WCS was performed by HPAEC. Chromatographic profiles (Figure 2) show two types of oligosaccharides, linear and branched, as described in previous research (4) . Peaks of linear oligosaccharides were characterized using standard maltooligosaccharide solutions. Based on previous investigations, branched oligosaccharides were identified by the peaks present in between the linear oligosaccharide peaks (34, 35) . Maltose (G2) and maltotriose (G3) were the major linear products of the α-amylase reaction on WCS (Figure 2A ), while higher molecular weight branched oligosaccharide peaks represent maltooligosaccharides of DP>4 ( Figure 2B ). It should be noted that glucose intensity on the electrochemical detector is not proportional to its actual amount (36) . The main products are hydrolyzed with different efficiencies by the four enzyme subunits (37) .
Toggling of the mucosal α-glucosidases by different inhibitors
A combination of the four mucosal MGAM and SI enzyme subunits is required for effective digestion of the LM-αLDx mixture to glucose; therefore, differential inhibition of individual mucosal α-glucosidase activities, or toggling of the enzymes, is hypothesized to be one of the approaches for moderating blood glucose excursions, which would be desirable for Type 2 diabetics. As discussed above, inhibiting α-glucosidases in the small intestine to regulate carbohydrate digestion is currently applied to treating Type 2 diabetes (10). However partial inhibition to provide a slow and more preciselycontrolled digestion of starch would be preferable to high-level inhibition where the bulk of starch goes undigested to the large intestine and can cause discomfort and diarrhea (38) . Previous investigations have shown that mucosal α-glucosidase inhibitors such as acarbose and salacinol-based compounds differentially inhibit the four enzymes, using maltose as the substrate (9, 14) , In the present study, we investigated the control of starch digestion through the concept of "toggling" of differential inhibition of subunits.
Acarbose (1) demonstrated the "toggling" principle of selective inhibition of the four mucosal α-glucosidases. Figure 3 shows acarbose inhibition of the α-glucosidase enzymes, with LMαLDx as the substrate. Treatment with different acarbose concentrations and the same amount of each α-glucosidase subunit showed that different concentrations were required to inhibit each enzyme. As an example of the toggling effect, 5 nM acarbose effectively inhibited ctMGAM and ctSI, while N-terminal MGAM and SI were virtually uninhibited. ctMGAM has the highest activity of the four α-glucosidases and has high binding and hydrolysis properties for larger maltooligosaccharides (7, 39, 40) . Thus, it is possible that selective inhibition of C-terminal domains could provide slow glucose release by placing the onus of digestion onto the slower or more specific N-terminal subunits. We propose that compounds that affect only one or two subunits could be used to control starch digestion and glucose delivery in vivo. Figure 4 illustrates inhibition of the mucosal α-glucosidases on LM-αLDx hydrolysis by de-O-sulfonated kotalanol (6) . At a concentration of only 50 pmol, this compound showed 20% and 40% inhibition of ctMGAM and ctSI activity, respectively, while N-terminal subunits were not inhibited. Thus, de-O-sulfonated kotalanol (6) can toggle off the C-terminal subunits, particularly ctSI, which has sucrase activity, while having little effect on the Nterminal subunits. It follows that de-O-sulfonated kotalanol (6) might be applicable as a blood glucose regulator for sucrose digestion as well as starch hydrolysis.
The toggling effect by C-3′-β-maltoseextended de-O-sulfonated ponkoranol (10) on LMαLDx hydrolysis showed that there were almost no inhibitory effects below 50 pmol ( Figure 5 ). Each α-glucosidase showed a different inhibitor susceptibility at 500 pmol of C-3′-β-maltoseextended de-O-sulfonated ponkoranol (10) . While ctMGAM and ntMGAM were inhibited about 50% at this concentration, the SI subunits showed a different inhibitory pattern: 70% inhibition of ctSI and 20% ntSI.
C-5′-β-maltose-extended de-O-sulfonated ponkoranol (11) also did not inhibit any of the α-glucosidases at concentrations below 50 pmol ( Figure 6 ). In this case, all four subunit activities were simultaneously and abruptly decreased at concentration over 500 pmol. Owing to this similar inhibitory property on all the subunits at the same concentration of inhibitor, C-5′-β-maltoseextended de-O-sulfonated ponkoranol (11) would not be applicable as an inhibitor for differential inhibition of the mucosal α-glucosidases.
IC 50 values of inhibitors on mucosal α-glucosidases with α-amylolyzed starch
As the IC 50 value is variable and depends on the amount of enzyme, type of inhibitor, substrate concentration as well as reaction conditions (41), we used a common concentration of protein (30 µg/mL) of each mucosal α-glucosidase, all of which have roughly the same molecular weight. IC 50 values with four different inhibitors (1, 6, 10, and 11) were determined using waxy corn starch-derived LM-αLDx by pancreatic α-amylase as well as maltose, for purposes of comparison. Table 2 shows that a relatively similar pattern of IC 50 values was obtained using LMαLDx and maltose, although the absolute values were different. The likely explanation is that the LM-αLDx mixture contains a significant fraction of maltose, as well as maltotriose, maltotetraose, and small branched glucan (α-LDx) structures (Figures 2A and B) . The longer linear maltooligosaccharides or branched oligosaccharides would generate different IC 50 values since MGAM and SI have different hydrolytic activities depending on chain length and linkages (5, 42, 43) .
The IC 50 value of acarbose (1) against ctMGAM (0.12 ± 0.01 nM) was about 500 times lower than against ntMGAM (62 ± 14 nM). Similarly, the IC 50 for ctSI (0.4 ± 0.4 nM) was approximately 300 times lower than for ntSI (135 ± 18 nM). Therefore, acarbose shows selectivity for inhibition of C-terminal MGAM and SI over N-terminal units. The inhibition constant (K i ) values previously reported for the N-terminal enzymes also were higher than ctMGAM and ctSI (14) . The structural basis for this preference for the C-terminal subunits was proposed to be the presence of additional saccharide subsites in the ctMGAM structure as compared to ntMGAM (7, 14) . This was subsequently supported by the crystal structure of the complex of ctMGAM with acarbose (44) .
The IC 50 values for different α-glucosidases in the presence of de-O-sulfonated kotalanol (6) on LM-αLDx were: ctMGAM (0.28 ± 0.02 nM), ntMGAM (0.13 ± 0.01 nM), ctSI (0.22 ± 0.13 nM), and ntSI (0.98 ± 0.04 nM). Thus, de-O-sulfonated kotalanol at relatively low concentration inhibits effectively three of the mucosal α-glucosidases, and shows limited selectivity over ntSI. Mucosal α-glucosidase reaction on LM-αLDx in the presence of C-3′-β-maltose-extended de-O-sulfonated ponkoranol (10) showed a nearly similar range of the IC 50 values for ctMGAM (0.58 ± 0.01 nM), ntMGAM (0.69 ± 0.01 nM) and ctSI (0.17 ± 0.02 nM). ntSI had 3-15 times higher IC 50 value (2.69 ± 0.29 nM). Thus, this compound shows potential for selective inhibition of ctSI, for hydrolyzing α-amylolyzed starch molecules. Alternatively, at a moderate concentration, it could be used to toggle off the three former subunits, leaving only ntSI active.
As shown above, C-5′-β-maltose-extended de-O-sulfonated ponkoranol (11) exhibited similar IC 50 values against all four mucosal subunits: ctMGAM (0.23 ± 0.02 nM), ntMGAM (0.12 ± 0.01 nM), ctSI (0.54 ± 0.01 nM), and ntSI (0.23 ± 0.01 nM). As in previous results with maltose hydrolysis (14,23), we observe that small changes in inhibitor structure can lead to different hydrolytic activity against LM-αLDx (Table 2) .
Conclusions
The results support the notion that the sulfonium-ion based inhibitors will be useful in deriving compounds that have the ability to inhibit each of the α-glucosidase enzymes units in real starch digestion. Furthermore, the data presented support the concept of controlling starch digestion rate through the "toggling" of activities of the mucosal α-glucosidases by selective enzyme inhibition. We propose, through the approach of differential inhibition by toggling of specific mucosal enzymes with inhibitors, that starch digestion rate may be modulated to attain similar effects as observed with slowly digestible starch which has the property of being digested throughout the small intestine (45). Decreasing initial peak glucose level and extending postprandial blood glucose delivery to the body can be desirable for diabetics and possibly to other groups vulnerable to metabolic syndromeassociated diseases. These candidates thus show promise as oral agents to moderate glucose release for the treatment of Type 2 diabetes. Ultimately, an assessment of compounds that can inhibit the activities of each enzyme in actual starch digestion will open the door to a better understanding of their roles in starch digestion individually and in combination. One unit (U) of enzyme activity was defined as 1 µM of glucose released from maltose (1%, w/v) or LM-αLDx (1%, w/v) in 1 min (µM/min). Data are shown as mean ± standard error of the mean (SEM). 
